The Competence and Willingness to Consent to Research Among Patients with Heroin Dependence.

Abstract:

BACKGROUND:Substance abuse research can raise ethical concerns about the comprehension and decision-making capacities of participants with drug dependence. In this study, the competence and willingness to consent to research participation were examined among patients with heroin dependence. METHODS:Twenty patients with heroin dependence and 24 healthy controls were asked to indicate if they would consent to participate in a low- and high-risk study. The MacArthur Competence Assessment Tool-Clinical Research was used to assess their consent capacities. RESULTS:Patients with heroin dependence and healthy controls did not differ significantly in their consent capacity scores. However, the patterns that underlay their decisions to consent and decline to participate in the two fictional studies were significantly different. Specifically, patients with heroin dependence were more likely to consent to participate in both studies, irrespective of the ratio of benefits to risks. Further, patients with heroin dependence who agreed to participate in the research studies did not demonstrate poorer decision-making capacities than their nonconsenting counterparts. CONCLUSIONS:Although the decision-making capacities of patients with heroin dependence and healthy controls were similar, the patterns that underlay their decisions to consent or decline to participate in the studies differed significantly between the two groups. Future studies should identify the specific factors that account for these emergent group differences.

journal_name

Ther Innov Regul Sci

authors

Zhao L,Shi H,Ying B,Li Q

doi

10.1007/s43441-020-00127-1

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

1106-1111

issue

5

eissn

2168-4790

issn

2168-4804

pii

10.1007/s43441-020-00127-1

journal_volume

54

pub_type

杂志文章
  • A Novel Collaborative Approach to Building Better Clinical Trials: New Insights From a Patient Engagement Workshop to Propel Patient-Centricity Forward.

    abstract:BACKGROUND:(1) A growing number of pharmaceutical and biotechnology organizations are engaging patients, their support networks, and clinical trial site staff at various touchpoints along the clinical research development spectrum to solicit feedback on how to reduce the burden of clinical trial participation and admin...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479019849875

    authors: Gregg A,Getz N,Benger J,Anderson A

    更新日期:2019-05-22 00:00:00

  • The Roles of Regulatory Science Research in Drug Development at the Pharmaceuticals and Medical Devices Agency of Japan.

    abstract::Recently, it is becoming increasingly difficult to develop innovative drugs. Thus, the role of regulatory science research in drug development and postmarketing settings has become more important. In this article, the authors discuss the roles of regulatory science research at the Pharmaceuticals and Medical Devices A...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479012469950

    authors: Asahina Y,Tanaka A,Uyama Y,Kuramochi K,Maruyama H

    更新日期:2013-01-01 00:00:00

  • Implementing the Principle of the 3 Rs Through the Indian Pharmacopoeia.

    abstract::Quality and safety tests are required for regulatory approval of drugs and pharmaceuticals in the country to guarantee minimum safety standards, and most of these tests include animal usage. In the case of biological medicines, these safety and quality tests have to be performed on a batch-to-batch basis and require a...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015572371

    authors: Rastogi S,Kalaivani M,Bhatia AK,Prakash J,Singh GN

    更新日期:2015-09-01 00:00:00

  • Study Designs in Multi-arm Trials for Breast Cancer: A Systematic Literature Review of Major Journals.

    abstract:BACKGROUND:Several articles showed that statistical efficiency of multi-arm randomized clinical trials (RCTs) is much better than conventional two-arm RCTs. Multi-arm RCTs attract interest mainly when the experimental treatment regimen is not optimized or several pipelines under development exist. Breast cancer is a po...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00141-3

    authors: Nomura S,Miyauchi Y,Ajisawa Y,Isogaya K,Sozu T

    更新日期:2020-09-01 00:00:00

  • Choosing a Mobile Sensor Technology for a Clinical Trial: Statistical Considerations, Developments and Learnings.

    abstract::The DIA Study Endpoints Community Working Group on Mobile Sensor Technology (MST) series addresses considerations that may be useful for selecting MST for use in a clinical trial. This article describes considerations regarding the selection of MST for clinical trials including expectations around technology specifica...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00188-2

    authors: Russell C,McCarthy M,Cappelleri JC,Wong S

    更新日期:2021-01-01 00:00:00

  • Principled Structured Incorporation of Clinical Knowledge Into Strategic Development Decisions.

    abstract::Efficient use of limited pharmaceutical product development resources requires integrating multiple attributes, such as efficacy, safety, pharmacology, and so on, to decide at any stage whether the development of a product should proceed aggressively or slowly or be terminated. The decision process proceeds most effec...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479014558273

    authors: Gould AL,Krishna R,Khan A,Saltzman J

    更新日期:2015-03-01 00:00:00

  • Investigating Rates of Food and Drug Administration Approvals and Guidances in Drug Development: A Structural Breakpoint/Cointegration Timeseries Analysis.

    abstract:BACKGROUND:The number of original and supplemental ANDAs, BLAs, NDAs, and Biosimilars FDA drug/biologic approvals (Approvals) has risen dramatically in the recent years, incidentally, so has the number of issued FDA guidances (Guidances). It is hypothesized that if the structures of the two timeseries are similar and/o...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00123-5

    authors: Daizadeh I

    更新日期:2020-09-01 00:00:00

  • Patient Experience Data in US Food and Drug Administration (FDA) Regulatory Decision Making:: A Policy Process Perspective.

    abstract:BACKGROUND:The influence of patient advocates on FDA regulatory decision making has increased. Despite enhanced engagement with FDA, there remain challenges to achieving the regulatory goals of patients within FDA's regulatory framework. Gaps exist between patient advocates' knowledge of the agency's processes and FDA'...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479017753390

    authors: Kuehn CM

    更新日期:2018-09-01 00:00:00

  • Rheumatoid Arthritis Disease Progression Modeling.

    abstract::Time progression models provide a significant advantage in developing clinical trials and can also be used to elicit comparisons among therapeutic agents. The authors performed a meta-analysis to construct a time progression model for rheumatoid arthritis (RA), an area of significant interest for pharmaceutical develo...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479013499571

    authors: Reeve R,Pang L,Ferguson B,O'Kelly M,Berry S,Xiao W

    更新日期:2013-11-01 00:00:00

  • Statistical Considerations on Clinical Efficacy Studies of Biosimilar for PMDA Submission.

    abstract::In general, similar to FDA and other health authorities, the PMDA requires clinical efficacy study(ies) to evaluate equivalence between a reference biological product and a Biosimilar product for new drug applications. Even if an identical clinical efficacy study is included in both of PMDA and FDA submissions, the co...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00133-3

    authors: Asami Y,Pan J,Oh M,Sato A

    更新日期:2020-09-01 00:00:00

  • A Framework for Managing the Minimal Clinically Important Difference in Clinical Trials.

    abstract::There is a long history of discussions about what is a minimal clinically important difference (MCID) and how this term applies to clinical research. This paper deals with a practical framework for MCID and its applicability to clinical trials. A literature review on the topic confirmed the fundamental role of MCID fo...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479013487541

    authors: Koynova D,Lühmann R,Fischer R

    更新日期:2013-07-01 00:00:00

  • Differences in Clinical Research Perceptions and Experiences by Age Subgroup.

    abstract:BACKGROUND:(1) To assess the differing viewpoints of actual and potential adult clinical trial participants in 5 age cohorts, (2) identify misperceptions and opportunities to reduce unnecessary burdens on volunteers, and (3) provide age-specific feedback to study sponsors on their current engagement efforts. METHODS:B...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-019-00033-1

    authors: Anderson A,Borfitz D,Getz K

    更新日期:2020-01-01 00:00:00

  • How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement.

    abstract:BACKGROUND:Pediatric regulations enacted in both Europe and the USA have disrupted the pharmaceutical industry, challenging business and drug development processes, and organizational structures. Over the last decade, with science and innovation evolving, industry has moved from a reactive to a proactive mode, investin...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00116-4

    authors: Severin T,Corriol-Rohou S,Bucci-Rechtweg C,An Haack K,Fuerst-Recktenwald S,Lepola P,Norjavaara E,Dehlinger-Kremer M,EFGCP Children’s Medicines Working Party.,Haertter S,Cheung SYA,IQ Pediatric Working Group.

    更新日期:2020-09-01 00:00:00

  • Development and Validation of a Brief Measure of Self-Management Competence: The Self-Management Self-Test (SMST).

    abstract:BACKGROUND:Self-management can be considered a way of dealing with oneself and relates to actions undertaken to create order, discipline, and control. The concept is closely linked to concepts of self-efficacy and self-regulation but can be distinguished from these. The Self-Management Self-Test (SMST) is a 5-item asse...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479019849879

    authors: Wehmeier PM,Fox T,Doerr JM,Schnierer N,Bender M,Nater UM

    更新日期:2019-07-14 00:00:00

  • An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency.

    abstract:BACKGROUND:This study compared the timing, regulatory marketing authorization decisions, and the final labeling for products submitted to Swissmedic to those submitted to European Medicines Agency (EMA) and the US Food & Drug Administration (FDA). METHODS:The Centre for Innovation in Regulatory Science (CIRS) conducte...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479016655841

    authors: Dörr P,Wadworth A,Wang T,McAuslane N,Liberti L

    更新日期:2016-11-01 00:00:00

  • Validation of QT Interval Correction Methods When a Drug Changes Heart Rate.

    abstract::The QT interval is correlated with heart rate; therefore, the QT interval is usually corrected by heart rate when drug-induced QT effect is studied. Currently, there are many correction methods that use either fixed or data-driven approaches. The effectiveness of correction methods depends on many factors and varies f...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479012467018

    authors: Dang Q,Zhang J

    更新日期:2013-03-01 00:00:00

  • How FDA Advisory Committee Members Prepare and What Influences Them.

    abstract::Since 1992 many changes have occurred in the regulations, guidelines, and processes governing the FDA, the biomedical industry, other stakeholders, and their interactions. Of particular importance, the FDA Amendments Act of 2007 made public advisory committee meetings mandatory for new molecular entities and devices r...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/0092861512458096

    authors: McIntyre TD,Pappas M,DiBiasi JJ

    更新日期:2013-01-01 00:00:00

  • A Practical Estimation Method for Analyzing Adverse Drug Reactions Using Data Mining.

    abstract::This study aimed to determine the potentially severe chemical properties of drugs that can cause adverse drug reactions (ADRs) such as erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) by using a data mining method. The study data were extracted from the Adverse Event Repor...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/0092861512460759

    authors: Shirakuni Y,Okamoto K,Uejima E,Inui S,Takahara JI,Ohgaru T,Yamasaki H,Tian Y,Kawashita N,Inoue R,Yasunaga T,Takagi T

    更新日期:2013-03-01 00:00:00

  • Communicating Immunogenicity-Associated Risk in Current U.S. FDA Prescription Drug Labeling: A Systematic Evaluation.

    abstract:BACKGROUND:Communicating the clinical impact of immunogenicity in labeling is important for safe and effective use of certain prescription products. Current U.S. Food and Drug Administration (FDA) guidance does not provide comprehensive recommendations on the communication of clinical impact of immunogenicity in labeli...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00161-z

    authors: Guinn D,Madabushi R,Wang YM,Brodsky E,Zineh I,Maxfield K

    更新日期:2020-11-01 00:00:00

  • Sentiment of Media Coverage and Reputation of the Pharmaceutical Industry.

    abstract:BACKGROUND:Patients and health care professionals receive information about pharmaceutical companies through various sources, including but not limited to print media, social media, and electronic media. The objective of this research was to benchmark the sentiment of electronic newspaper media coverage between 2014 an...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-019-00048-8

    authors: Pampulevski V,Giaquinto JR,Rametta M,Toscani M,Barone J,Nadal JC

    更新日期:2020-01-01 00:00:00

  • Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker-Driven Phase III Trial.

    abstract:BACKGROUND:The design and sample size of a phase III study for new medical technologies were historically determined within the framework of frequentist hypothesis testing. Recently, drug development using predictive biomarkers, which can predict efficacy based on the status of biomarkers, has attracted attention, and ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00119-1

    authors: Takazawa A,Morita S

    更新日期:2020-09-01 00:00:00

  • Regulatory Perspective of International Agencies for Development of Biosimilar Products (Monoclonal Antibodies): An Overview.

    abstract::Biopharmaceutical medicines are complex molecules obtained from a living organism (plant or animal cells) and may contain components of a living organism using biotechnology. Biosimilars are closely similar to already approved biopharmaceutical products that could form a new generation of medicines that are available ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章,评审

    doi:10.1007/s43441-020-00112-8

    authors: Sharma A,Khante S,Mahadik KR,Gaikwad VL

    更新日期:2020-09-01 00:00:00

  • Evaluation of the Performance of the South Africa Regulatory Agency: Recommendations for Improved Patients' Access to Medicines.

    abstract:BACKGROUND:Timely access to new medicines may be addressed through strengthening of registration efficiencies and timelines by establishing and refining value-added registration processes, resources, and systems. The aims of this study were to evaluate the timelines of the milestones of the South African review process...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-019-00013-5

    authors: Keyter A,Salek S,Gouws J,Banoo S,Walker S

    更新日期:2020-07-01 00:00:00

  • Alternative New Mono-scaled Quantitative Benefit-Risk Assessment of Human Papillomavirus Vaccine in Japan.

    abstract:BACKGROUND:The human papillomavirus (HPV) vaccine coverage is very low in Japan since the government suspended the active encouragement of the vaccination. We aimed to conduct a benefit-risk assessment of HPV vaccination and explore different consequent scenarios to identify potential improvements to the current Japane...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1007/s43441-020-00189-1

    authors: Matsumoto T,Matsumaru N,Scuffham P,Neels P,Tsukamoto K

    更新日期:2021-01-01 00:00:00

  • Effective Partnering in Conducting Benefit-Risk Patient Preference Studies: Perspectives From a Patient Advocacy Organization, a Pharmaceutical Company, and Academic Stated-Preference Researchers.

    abstract:BACKGROUND:Formal incorporation of patients' perspectives is becoming increasingly important in medical product development and decision making. This article shares practical advice regarding how patient advocacy organizations, the pharmaceutical industry, and academic experts in stated-preference research can effectiv...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479017746404

    authors: Wolka AM,Fairchild AO,Reed SD,Anglin G,Johnson FR,Siegel M,Noel R

    更新日期:2018-07-01 00:00:00

  • Interdisciplinary Safety Evaluation and Quantitative Safety Monitoring: Introduction to a Series of Papers.

    abstract::The American Statistical Association and DIA have created an interdisciplinary working group of drug safety experts from academia, industry and regulatory backgrounds to explore the future direction for safety monitoring. This introduction to the series explains the background and rationale for this special section. ...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479018793130

    authors: Seltzer JH,Li J,Wang W

    更新日期:2019-03-29 00:00:00

  • Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors.

    abstract::Expanded access is a regulatory mechanism by which an investigational drug can be made available outside of a clinical trial to treat patients with serious or life-threatening conditions for which there are no satisfactory treatment options. An expanded access program (EAP) is the formal plan under which preapproval a...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479015578154

    authors: Klopfenstein M,Van Campen LE,Garnett T

    更新日期:2015-05-01 00:00:00

  • Risk Evaluation and Mitigation Strategies With Elements to Assure Safe Use: Alignment of the Goals With the Tools to Manage Risk.

    abstract::The Food and Drug Administration Amendments Act of 2007 gave the FDA the authority to require drug sponsors to submit a risk evaluation and mitigation strategies (REMS) program for those medicines with serious risks such that failure to effectively manage these risks would tip the benefit-risk balance. As of August 8,...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479014527749

    authors: Cronin M,Berger S,Seligman PJ

    更新日期:2014-11-01 00:00:00

  • Adaptive Design: Results of 2012 Survey on Perception and Use.

    abstract::Adaptive designs are increasingly used in clinical trials. The Drug Information Association's Adaptive Design Scientific Working Group (ADSWG) works to foster collaboration among regulatory agencies, academia, and pharmaceutical and biotech companies to further the science of adaptive clinical development. The ADSWG S...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479014522468

    authors: Morgan CC,Huyck S,Jenkins M,Chen L,Bedding A,Coffey CS,Gaydos B,Wathen JK

    更新日期:2014-07-01 00:00:00

  • Product Registration in Developing Countries: A Proposal for an Integrated Regional Licensing System Among Countries in Regional Economic Blocs.

    abstract::The product pipeline for diseases that disproportionately affect the developing world has considerably expanded over the last decade. Indeed, there are about 134 products for these diseases in the pipeline, including vaccines, drugs, diagnostics, microbicides, and vector control tools, and dozens of these products are...

    journal_title:Therapeutic innovation & regulatory science

    pub_type: 杂志文章

    doi:10.1177/2168479013478952

    authors: Saidu Y,De Angelis D,Aiolli S,Stefano G,Georges AM

    更新日期:2013-05-01 00:00:00